Post-mastectomy chest wall recurrence, Xeloda chemo with radiation – pro
Local recurrence rates of breast cancer after mastectomy alone have been reported as high as 45% for those with T3/T4 or node positive disease.1,2 Treatment for patients that recur in the setting of previous mastectomy and PMRT is quite problematic. Options for additional therapy may include surgery, chemotherapy, or re-irradiation with or without sensitization (i.e. concurrent chemotherapy or hyperthermia).3. Among sensitizors, capecitabine has been studied 4. It is considered acceptable per peer reviewed literature, for example, ESMO recommends a consideration the approach of sensitization with capecitabine in chest wall recurrent disease.
Timothy M. Zagar et al, Durable palliation of breast cancer chest wall recurrence with radiation therapy, hyperthermia, and chemotherapy. Radiother Oncol. 2010 Dec; 97(3): 535540.
Florian Darschmidt et al, Reirradiation of recurrent breast cancer with and without concurrent chemotherapy. Radiation Oncology20083:28
F. Cardoso et al, ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol (2014) doi: 10.1093/annonc/mdu385
Alshimaa M Alhanafy, Tarek A Hashem, Mohamed Abu El-Fetouh, Ashraf E Abd El-Ghany, Ehab A Shaltout, Safety and feasibility of concurrent capecitabine and hypofractionated postmastectomy radiotherapy. Manoufia Med Journal Year : 2015 | Volume : 28 | Issue : 2 | Page : 325-332